Non-small cell lung cancer: miR-30d suppresses tumor invasion and migration by directly targeting NFIB

Yubing Wu1, Jingnan Zhang2, Shizhen Hou1

  • 1Department of Thoracic Surgery, Linyi Central Hospital of Shandong, Jiankang Road No. 17, Linyi, 276400, People's Republic of China.

Biotechnology Letters
|September 2, 2017
PubMed
Abstract

Insights

MicroRNA-30d (miR-30d) is downregulated in non-small cell lung cancer (NSCLC). It suppresses tumor cell migration and invasion by targeting Nuclear factor I B (NFIB).

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Non-small cell lung cancer (NSCLC) is a major cause of cancer-related mortality.
  • The role of microRNAs (miRNAs) in NSCLC pathogenesis is an active area of research.
  • Understanding the molecular mechanisms underlying NSCLC progression is crucial for developing effective therapies.

Purpose of the Study:

  • To investigate the function of miR-30d in non-small cell lung cancer (NSCLC).
  • To elucidate the molecular mechanism by which miR-30d influences NSCLC progression.

Main Methods:

  • Quantitative reverse transcription polymerase chain reaction (qRT-PCR) to assess miR-30d expression levels.
  • Cell migration and invasion assays in NSCLC cell lines.
  • Luciferase reporter assay to validate direct targeting of Nuclear factor I B (NFIB) by miR-30d.
  • Overexpression studies of miR-30d and NFIB in NSCLC cell lines.

Main Results:

  • miR-30d was frequently downregulated in NSCLC tissues and cell lines.
  • Downregulation of miR-30d correlated with specific clinicopathological features in NSCLC patients.
  • Overexpression of miR-30d significantly inhibited cell migration and invasion in NSCLC.
  • miR-30d directly targets the 3'-untranslated region (3'-UTR) of Nuclear factor I B (NFIB) mRNA.
  • NFIB overexpression partially reversed the inhibitory effects of miR-30d on cell migration and invasion.

Conclusions:

  • miR-30d acts as a tumor suppressor in NSCLC by inhibiting cell migration and invasion.
  • The mechanism involves direct targeting of Nuclear factor I B (NFIB) by miR-30d.
  • NFIB partially counteracts the tumor-suppressive functions of miR-30d in NSCLC.